Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-202 (PD1-PDL1 inhibitor 2) 是一种非肽类 PD-1/PD-L 复合物抑制剂,其 IC50为 18 nM,KD 为 8 μM。它与 PD-L1 直接结合并阻断人类 PD-1/PD-L 的相互作用,具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 311 | 现货 | ||
5 mg | ¥ 925 | 现货 | ||
10 mg | ¥ 1,432 | 现货 | ||
25 mg | ¥ 2,953 | 现货 | ||
50 mg | ¥ 3,490 | 现货 | ||
100 mg | ¥ 4,990 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 976 | 现货 |
产品描述 | BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction. |
靶点活性 | PD-1/PD-L1 interaction:0.018 μM |
体外活性 | BMS-202 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to a number of histologically distinct tumors. Blockade of the PD-1/PD-Ll ligation using antibodies to PD-Ll has been shown to restore and augment T cell activation in many systems[1]. |
激酶实验 | All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively). |
别名 | PD1-PDL1 inhibitor 2, PD-1/PD-L1 inhibitor 2 |
分子量 | 419.52 |
分子式 | C25H29N3O3 |
CAS No. | 1675203-84-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 76 mg/mL(181.2 mM)
Ethanol: 83 mg/mL (197.85 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.3837 mL | 11.9184 mL | 23.8368 mL | 59.5919 mL |
5 mM | 0.4767 mL | 2.3837 mL | 4.7674 mL | 11.9184 mL | |
10 mM | 0.2384 mL | 1.1918 mL | 2.3837 mL | 5.9592 mL | |
20 mM | 0.1192 mL | 0.5959 mL | 1.1918 mL | 2.9796 mL | |
50 mM | 0.0477 mL | 0.2384 mL | 0.4767 mL | 1.1918 mL | |
100 mM | 0.0238 mL | 0.1192 mL | 0.2384 mL | 0.5959 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS-202 1675203-84-5 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 BMS202 antitumor PD1-PDL1 inhibitor 2 PD-1/PD-L1 inhibitor 2 dimeric anti-proliferation BMS 202 nonpeptidic immune-response Thermal stabilization Inhibitor inhibit hydrophobic inhibitor